米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床效果及安全性

发布时间：2018-11-21 16:29

【摘要】：目的:探讨米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床效果及安全性。方法:选择2012年6月—2014年6月我院接诊的60例子宫肌瘤患者进行研究,随机分为观察组和对照组。观察组30例,采用米非司酮联合血府逐瘀胶囊治疗。对照组30例,采用米非司酮。比较两组患者的子宫体积及子宫肌瘤的体积、激素含量(LH、FSH、P、E2)、治疗效果及不良反应(恶心,头痛,乏力)。结果:治疗后,观察组患者与对照组患者子宫的体积相比有统计学差异,观察组小于对照组(t=9.3029,P=0.0003);观察组患者的子宫肌瘤的体积小于对照组患者,两者相比有统计学差异(t=3.8804,P0.0001);观察组患者的LH、FSH、P、E2含量均小于对照组患者,两者相比有统计学差异(P0.05);观察组的治疗效果优于对照组,两者相比有统计学差异(u=2.4591,P=0.0139);不良反应比较中,观察组与对照组的术后头痛发生比率为0.00%和13.33%,两者相比有统计学差异(χ2=4.2857,P=0.0384);观察组与对照组的不良反应总的发生比率为6.67%和36.67%,两者相比有统计学差异(χ2=7.9542,P=0.0048)。结论:米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床疗效良好,安全性较高,预后良好,值得临床推广。
[Abstract]:Objective: to investigate the clinical effect and safety of mifepristone combined with Xuefu Zhuyu capsule in the treatment of uterine leiomyoma. Methods: from June 2012 to June 2014, 60 patients with uterine leiomyoma were randomly divided into observation group and control group. In the observation group, 30 cases were treated with mifepristone combined with Xuefu Zhuyu capsule. The control group (30 cases) was treated with mifepristone. The volume of uterus, volume of uterine leiomyoma, hormone content (LH,FSH,P,E2), therapeutic effect and adverse reactions (nausea, headache, fatigue) were compared between the two groups. Results: after treatment, there was a significant difference in the volume of uterus between the observation group and the control group, which was smaller than that in the control group (t 9.3029 Pu 0.0003). The volume of uterine leiomyoma in the observation group was smaller than that in the control group, and there was statistical difference between the two groups (t = 3.8804, P 0.0001). The content of LH,FSH,P,E2 in the observation group was lower than that in the control group (P0.05), the therapeutic effect of the observation group was better than that of the control group, and there was statistical difference between the two groups. The incidence of postoperative headache in the observation group and the control group was 0.00% and 13.33 respectively, and there was a significant difference between the two groups (蠂 ~ 2 / 4.2857 / P ~ (0.0384). The overall incidence rates of adverse reactions in the observation group and the control group were 6.67% and 36.67%, respectively. There was a significant difference between the two groups (蠂 ~ 2 = 7.9542, P < 0.0048). Conclusion: mifepristone combined with Xuefu Zhuyu capsule in the treatment of uterine leiomyoma has good clinical efficacy, high safety and good prognosis.
【作者单位】：义乌市中心医院妇产科;
【分类号】：R737.33

【参考文献】